Semaglutide's Safety and Absorption in Patients with Liver Impairment
Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function
Background
Semaglutide, a potent GLP-1 receptor agonist widely used for Type 2 Diabetes and weight management, is primarily eliminated via metabolic pathways, with renal excretion playing a minor role. However, the impact of hepatic impairment (reduced liver function) on the drug's pharmacokinetics (how the body absorbs, distributes, metabolizes, and excretes a drug) and overall safety profile has not been fully characterized. This study specifically aimed to investigate how varying degrees of liver dysfunction affect semaglutide's exposure in the body and its tolerability.
TitrateLab articles covering Semaglutide
Written by TitrateLab, separately from the study summarized above.
